{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:52:37Z","timestamp":1759481557131,"version":"3.44.0"},"reference-count":4,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.amjmed.2004.04.020","type":"journal-article","created":{"date-parts":[[2004,9,16]],"date-time":"2004-09-16T10:10:39Z","timestamp":1095329439000},"page":"444-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases"],"prefix":"10.1016","volume":"117","author":[{"given":"Kosaku","family":"Nitta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nihei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2004.04.020_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0272-6386(01)80115-3","article-title":"Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications","volume":"37","author":"Epstein","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2004.04.020_bib2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.04.020_bib3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11906-003-0087-9","article-title":"RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease","volume":"5","author":"Lakkis","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.amjmed.2004.04.020_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934304004346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934304004346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:30:08Z","timestamp":1757579408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934304004346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":4,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0002934304004346"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2004.04.020","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2004.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}